Diseases caused by helminth infections affect more than a quarter of the population of the world, but the therapeutic arsenal is limited. The approval of moxidectin in 2018 and triclabendazole in 2019 by the FDA marked an important moment in the fight against diseases of poverty, such as helminthiases.

中文翻译：

---

FDA批准的21世纪抗寄生虫药：蠕虫病成功了吗？

由蠕虫感染引起的疾病影响世界四分之一以上的人口，但是治疗性武器库却很有限。FDA于2018年批准了莫昔克丁和2019年批准了三苯达唑，这标志着抗击蠕虫病等贫困疾病的重要时刻。